eyestock logo

eyestock

KR

Korro Bio IncNASDAQ KRRO

Последний отчетный период 30 июня, 2024

Обновлено 20 дек., 2024

Последняя цена

Капитализация млрд. $

0.465

Micro

Биржа

XNAS - Nasdaq

Анализ акций KRRO

KR

Нет оценки

Количественный анализ Eyestock не покрывает акции Korro Bio Inc.

Капитализация млрд. $

0.465

Дивидендная доходность

Оборот

9.27 млрд

Сайт компании

https://www.korrobio.com/

Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2019-10-03. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.

Смотреть Секцию: Рейтинг